Arcus Biosciences to Participate in Two Upcoming December 2025 Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in December: 8 th Annual Evercore Healthcare Conference Date: Tuesday, December 2 nd , 2025 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 4:40 p.m. ET Citi’s 2025 Global Healthcare Conference Date: Wednesday, December 3 rd , 2025 Location: Miami, FL Format: Fireside chat & 1x1 meetings Time: 10:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com . Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com . Contacts Investor Inquiries Pia Eaves (Banerjee) VP of Investor Relations & Strategy (617) 459-2006 peaves@arcusbio.com Media Inquiries Holli Kolkey VP of Corporate Affairs (650) 922-1269 hkolkey@arcusbio.com Maryam Bassiri AD, Corporate Communications (510) 406-8520 mbassiri@arcusbio.com